secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0001193125-24-184871
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks appoints Leone Patterson as EVP, Chief Business & CFO effective Sept 1, 2024
--------------------------------------------------------------------------------

- Ms. Patterson appointed EVP, Chief Business Officer and CFO; start date Sept 1, 2024.
- Kenneth Galbraith to step down as interim CFO but remain Chair and CEO.
- Compensation: $485K base salary, 45% bonus target, $50K signing bonus, 360,000 inducement stock options.
- Amended Inducement Plan increases share reserve by 700,000 shares to 1,450,000 total since plan inception.
- Ms. Patterson brings over 20 years biotech CFO/CEO experience from Tenaya, Adverum, etc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524184871/0001193125-24-184871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524184871/d810428d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-184871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer